Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

AI drug discovery specialist Generate Biomedicines has raised $400 million in the year’s largest initial public offering to date for a biotechnology firm. The company, which was launched in 2018 by ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

Generate is indicative of a more mature startup that may have a better chance of succeeding in today’s markets. Industry IPOs peaked in 2021, resulting in a flood of companies whose early science didn ...

You might be familiar with how Python and C can work together, by way of projects like Cython. The new PythoC project has a unique twist on working with both languages: it lets you write ...

PythoC lets you use Python as a C code generator, but with more features and flexibility than Cython provides. Here’s a first look at the new C code generator for Python. Python and C share more than ...

Dow is applying a systems approach across the vehicle lifecycle, from material design and component engineering to recycling infrastructure and end-of-life vehicle recovery. As the automotive industry ...